Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Announcement PICI Welcomes New UCSF Center Director Announcement New Staff Members Join PICI Announcement PICI Members and Partners Featured at #CARTCR Announcement, Our Impact PICI Network Researchers Featured at #IO23ASGCT Announcement, Our Impact, Press Release Developing Next-Gen Scientific Leaders Announcement, Our Impact PICI Network Researchers at #ASCO23 Announcement, Partner Highlight Guardant Health, PICI Launch Research Collaboration